Search the Newsreel

BMS Chooses Houston for $2.3B Manufacturing Facility

Bristol Myers Squibb (BMS) has selected Houston as the location for a new $2.3 billion multi-modal manufacturing campus. This facility, part of BMS's $40 billion U.S. investment, will support the production of various treatments including small molecules, biologics, and ADCs. The campus aims to …

Pharma giant bets $2.3B on massive new Houston campus

Bristol Myers Squibb has chosen Houston for a new $2.3 billion manufacturing campus at Generation Park. This massive 600,000-square-foot facility is expected to create nearly 500 skilled jobs and approximately 2,000 indirect jobs during its construction phase. The investment is part of the company's …

New Bristol Myers Squibb facility coming to Generation Park

Global biopharmaceutical company Bristol Myers Squibb is set to establish a new pharmaceutical manufacturing campus in the Houston area, specifically near Generation Park. FOX 26's Karys Belger reported on this development. The facility will mark a significant expansion for the company in the region.

Bristol Myers Squibb to expand in Harris County

The article states that Bristol Myers Squibb plans to expand its operations in Harris County. No further details are provided regarding the nature or scope of this expansion.

Pharmaceutical giant to build $2.3B plant, create 500 jobs in Texas

Bristol Myers Squibb is investing $2.3 billion to construct a new drug manufacturing campus in Houston, Texas, creating nearly 500 initial jobs and 2,000 construction jobs. The 600,000-square-foot facility at Generation Park will produce various next-generation medicines. Texas Governor Greg Abbott praised the investment, …

Bristol Myers Squibb to build $2.3 billion Houston campus

Bristol Myers Squibb announced Monday it will build a $2.3 billion drug manufacturing campus in Houston, Texas, part of the company's broader $40 billion commitment to invest in the United States over five years. The roughly 600,000-square-foot campus will be located at Generation Park, …

Bristol Myers Squibb selects Generation Park for new $2.3B manufacturing campus

Bristol Myers Squibb has chosen Generation Park in northeast Houston for its new $2.3 billion manufacturing campus, a project anticipated to create nearly 500 jobs directly and 2,000 construction jobs. The 600,000-square-foot facility will produce various medicines, supporting the company's $40 billion investment in …

Bristol Myers Squibb opening pharmaceutical manufacturing campus near Houston

Bristol Myers Squibb is establishing a new $2.3 billion pharmaceutical manufacturing campus in Generation Park near Houston, expected to create nearly 500 new permanent jobs and 2,000 construction jobs. This marks the second major pharmaceutical investment in the area, following Eli Lilly's plans for …

Bristol Myers To Invest $2.3 Bln In Houston Manufacturing Campus; To Create 500 Skilled Jobs

(RTTNews) - Bristol Myers Squibb (BMY) announced Monday an investment of approximately $2.3 billion in the U.S., while selecting Houston, Texas, as the site for a new, state-of-the-art multi-modal manufacturing campus to accelerate the delivery of next-generation medicines to patients. The approximately 600,000 square …

Bristol Myers to build $2.3 billion manufacturing site in Houston

Bristol Myers Squibb announced a $2.3 billion investment to construct a new manufacturing facility in Houston, Texas, creating nearly 500 skilled jobs and approximately 2,000 construction jobs. This initiative is part of the company's $40 billion commitment to U.S. investments and aligns with a …

Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas

New State-of-the-Art Facility Will Create Nearly 500 Skilled Jobs and Accelerate the Delivery of Next-Generation Medicines Investment Furthers BMS' $40 Billion Commitment to American Innovation, Manufacturing and Economic Growth PRINCETON, N.J., August 10, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced the selection of Houston, …

Weekly Recap: Merger talks with Bristol Myers and Imjudo launch in China

AstraZeneca (AZN) has been involved in preliminary merger discussions with Bristol Myers Squibb, which reportedly led to a dip in AZN's share price. Concurrently, AstraZeneca is focusing on organic growth, marked by the launch of its cancer drug Imjudo in China, a new biologics …

Bristol Myers Squibb Invests $2.3B in New Houston Pharma Facility

Bristol Myers Squibb is investing $2.3 billion to construct a 600,000-square-foot manufacturing facility at Generation Park in northeast Houston, expected to create nearly 500 jobs. This significant investment further establishes Houston as a leading hub for life sciences and advanced manufacturing, following similar large-scale …

Noticias de acciones de Bristol-Myers Squibb Co (BMY)

The Bull Case For Bristol Myers Squibb (BMY) Could Change Following Expanded Schrödinger Bunsen AI Partnership

What the AstraZeneca-BMS rumors reveal about pharma megamergers

Reports of a potential megamerger between AstraZeneca and Bristol Myers Squibb, which would have created a $400 billion pharmaceutical giant, were quickly disputed. While AstraZeneca's strong pipeline makes a merger less appealing for them, Bristol Myers Squibb could benefit due to impending patent expirations …

Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions

Beyond the Megamerger: How Rumored AstraZeneca–BMS Discussions Signal a New Era of Pharmaceutical Competition

Rumors of a potential AstraZeneca-Bristol Myers Squibb merger, despite being disputed, highlight a fundamental shift in pharmaceutical competition. The article suggests that future success in the industry will depend not just on scientific innovation, but on integrated capabilities including AI, resilient manufacturing, and diversified …

Bristol Myers Squibb (BMY) Stock Looks Reasonable Below Fair Value

CPI | AstraZeneca, Bristol Myers Dismiss Merger Talk Speculation

AstraZeneca Plc and Bristol Myers Squibb Co. have dismissed speculation regarding a potential merger, stating they are not engaged in such discussions. This clarification came after an earlier report by the Financial Times suggested talks were underway for a $400 billion deal, which caused …

Senior Source Denies AstraZeneca and Bristol Myers Deal Talks : Report

A senior source has denied any ongoing or historical discussions between AstraZeneca and Bristol Myers Squibb regarding a potential merger, contradicting earlier speculation about a nearly $400 billion deal. The denial follows initial reports that caused AstraZeneca's shares to drop, with the subsequent denial …

No deal between AstraZeneca and BMS, senior source insists: Reuters

Reuters has reported that rumors of a merger between AstraZeneca and Bristol Myers Squibb are false, according to a senior source close to the matter. This news deflates widespread speculation about what could have been the largest pharmaceutical deal in history, valued at approximately …

Senior source denied AstraZeneca and Bristol Myers Squibb were ever in merger talks

A senior source close to the matter denied that AstraZeneca and Bristol Myers Squibb were ever in merger talks, contradicting earlier reports of a potential $400 billion combination. This denial comes after AstraZeneca's shares dropped following the initial reports, while Bristol Myers Squibb's stock …

'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

A senior source close to the matter has stated that there are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb regarding a potential merger, dispelling recent reports of a mega deal. AstraZeneca's shares initially slid after the Financial Times reported on potential talks …

‘No discussions’ ongoing for AstraZeneca-BMS merger: Reuters

Reuters reported that there are no ongoing discussions between AstraZeneca and Bristol Myers Squibb regarding a potential merger, contradicting an earlier Financial Times report. The Financial Times report had caused AstraZeneca's stock to drop, while the Reuters news led to a rebound for AZ …

Bristol-Myers falls on report there are no talks going on with AstraZeneca

Bristol-Myers Squibb's stock fell 1.4% in premarket trading following a report that there are no ongoing discussions with AstraZeneca regarding a potential deal. Conversely, AstraZeneca's shares rose by 5.6% after the news. The report explicitly stated that no deal ever existed between the two …

Argus Upgrades Bristol-Myers Squibb to Buy From Hold, Price Target is $75

Argus has upgraded Bristol-Myers Squibb (BMY) to a "Buy" rating from "Hold," setting a new price target of $75. The company currently holds an average rating of "overweight" with a mean price target of $66 among analysts. The full MT Newswires article with further …

AstraZeneca and Bristol Myers Squibb Held Merger Talks | PharmExec

AstraZeneca and Bristol Myers Squibb recently held discussions about a potential merger that would create the world's largest pharmaceutical company by revenue, with a combined market capitalization of nearly $400 billion. The report, though unconfirmed by either company, led to a drop in AstraZeneca …

An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’

Analysts are describing a potential merger between AstraZeneca and Bristol Myers Squibb as "odd," despite its potential to create a major cancer-drug powerhouse. The Financial Times reported early-stage talks, leading to AstraZeneca shares closing lower and Bristol Myers Squibb remaining flat. This merger would …

Bristol Myers Squibb, AstraZeneca reportedly weigh $400B merger

U.K. drugmaker AstraZeneca and New Jersey-based Bristol Myers Squibb are reportedly in early-stage talks for a potential $400 billion merger. If successful, this tie-up would create the world’s fourth-largest drugmaker by market value and the largest by revenue, uniting their strengths in oncology, immunology, …

Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?

Bristol Myers Squibb Company (BMY) Hit a 52 Week High, Can the Run Continue?

An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.

Reports of a potential megamerger between AstraZeneca and Bristol Myers Squibb have been met with skepticism and a significant stock sell-off on Wall Street. Analysts are perplexed by AstraZeneca's interest, given its strong organic growth, while Bristol Myers faces patent expirations for key products. …

Jim Cramer Senses a 'Fake Out' in Rumored AstraZeneca, Bristol Myers Squibb $400 Billion Mega-Merger

Jim Cramer expressed skepticism regarding the rumored $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb, calling it a potential "fake out" and suggesting BMY needs assistance. The Financial Times reported ongoing discussions, which could lead to a cash and stock deal, combining AstraZeneca's …

Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea

The article argues that a potential merger between AstraZeneca and Bristol Myers Squibb, valued at nearly $400 billion, would be a disaster. It highlights severe regulatory concerns due to significant portfolio overlaps, potential pipeline disruptions, and massive job losses as key reasons against such …

AstraZeneca tops pharma growth rankings while Bristol Myers trails amid merger talks (XLV:NYSEARCA)

AstraZeneca leads pharmaceutical growth rankings with an 'A' Growth Grade, while Bristol Myers Squibb lags with a 'D' grade. This comes amidst reports that the two companies are exploring a merger, which would create one of the world's largest pharmaceutical firms. A merger would …